[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overactive-bladder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overactive-bladder":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,46,75,95,134,145,170,196,220,245,267,295,322,348,374,398,422,445,472,494,516,542,577,612,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053817","sacral-neuromodulation-for-male-overactive-bladder-moab-100053817",false,"NCT06511141","Sacral Neuromodulation for Male Overactive Bladder (MOAB)","Sacral Neuromodulation for Male Overactive Bladder","Key Inclusion Criteria:\n\n1. Participants aged ≥ 18 years at the time of enrollment\n2. Able to complete bladder diaries and patient questionnaires\n3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).\n4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year\n\nKey Exclusion Criteria:\n\n1. Any patient that is not a suitable candidate per investigator discretion\n2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment\n3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)\n4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices\n5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)\n6. Positive response to Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment\n7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician\n8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the discretion of the participating physician.\n9. Uncontrolled diabetes\n10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone","MALE","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.",[27,28,29,30,31,32],"Overactive Bladder","Urinary Urgency Incontinence","Benign Prostatic Hyperplasia","Prostate Cancer","Prostatectomy","Urinary Frequency","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2024-10-22",{"date":41,"type":21},"2028-12",{"name":43,"class":44},"Axonics, Inc.","INDUSTRY",21,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100644342","flyte-device-for-improving-urinary-incontinence-among-endometrial-and-cervical-cancer-survivors-who-have-undergone-radiation-therapy-100644342","NCT07662824","Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy","Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study","Inclusion Criteria:\n\n* Female patients who have received conventionally fractioned adjuvant or primary pelvic radiation therapy for endometrial or cervical cancer ≥ 3 months prior to registration\n* Age ≥ 21 years at enrollment\n* English speaking\n* Demonstrates understanding of the study protocol and has signed the Informed Consent Form (ICF)\n* Has a clinical diagnosis of urinary incontinence (stress urinary incontinence \\[SUI\\], urge urinary incontinence \\[UUI\\], mixed) or overactive bladder (OAB)\n* Ability to contract the pelvic floor muscles (PFMs) without pain\n* Ability to tolerate size 6 vaginal dilator\n* Internet access\n* Access to an iOS or Android smartphone or tablet with capabilities to download and use the Flyte app\n* Willing and able to participate in follow-up\n\nExclusion Criteria:\n\n* Participation in another clinical study which may interfere with study requirements\n* Currently receiving active cancer directed therapy (i.e., cytotoxic chemotherapy) in post hysterectomy patients\n* Completion of radiation therapy or surgery within 3 months of enrollment\n* Life expectancy is less than six months in the opinion of the investigator\n* Inability to tolerate insertion of the intravaginal wand. This will be recorded to support the usability of Flyte secondary endpoint\n* Suspected vesicovaginal or colovaginal fistula\n* Physical limitations that impede the patient's ability to participate (e.g., ability to grasp the wand and insert it and ability to turn on the Flyte controller unit)\n* Acute infection or hematuria\n* Inability to contract the PFMs or pain with contraction, as confirmed with intravaginal exam\n* Impaired cognitive function or neurologic conditions","FEMALE","21 Years",{"count":56,"type":21},44,[24],"This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation therapy. Urinary incontinence is common after pelvic radiation therapy and can affect daily life and well-being. Access to in-person pelvic floor physical therapy can be limited. The Flyte device is designed for in-home use to deliver a series of mechanical vibrations at a specific frequency while the pelvic floor muscles are contracting and relaxing (i.e., normal, guided Kegel exercises). This treatment is called mechanotherapy. The Flyte device may improve urinary incontinence symptoms, as well as overall quality of life among endometrial and cervical cancer survivors who have undergone radiation therapy.",[60,61,27,62],"Cervical Carcinoma","Endometrial Carcinoma","Voiding Disorders","NOT_YET_RECRUITING","2026-06-22",{"date":66,"type":37},"2026-06-23",{"date":68,"type":21},"2026-08-13",{"date":70,"type":21},"2028-08-13",{"name":72,"class":73},"Mayo Clinic","OTHER",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":74},"100642531","early-phase-1-self-start-triage-model-for-post-botox-lower-urinary-tract-symptoms-100642531","NCT07648290","Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms","Inclusion Criteria:\n\n* Female patients of all races and ethnicities aged 18 years and older.\n* Diagnosis of Overactive Bladder (OAB) and\u002For Urge Urinary Incontinence (UUI).\n* Scheduled to receive intradetrusor onabotulinumtoxinA (Botox®) for symptom management.\n* Has decision making capacity to provide informed consent and comply with and follow study protocols.\n* Ability to navigate a computer system independently\n* Access to MyChart and email account\n\nExclusion Criteria:\n\n* Patients who currently perform Clean Intermittent Catheterization (CIC) or have an indwelling catheter.\n* History of Severe Renal Impairment Cr\u002FCl - \\\u003C60 ml\u002Fmin 1.73m2\n* History of recurrent UTIs (defined as \\>3x symptomatic UTIs in 12 months).\n* Post-Void Residual (PVR) volume \\>150 mL.\n* Active UTI at the time of procedure (procedure cancellation criteria).\n* Patients currently on prophylactic antibiotics.\n* Inability to provide informed consent.",{"count":82,"type":21},260,[84],"EARLY_PHASE1","The primary objective of this study is to investigate whether providing a standing, take-home prescription for empiric Macrobid (self-start model) is superior to standard call-in\u002Furgent care triage (triage model) among patients undergoing intradetrusor Botox®. Urinary tract infections. (UTIs) are the most common complication with intradetrusor Botox®, and patients have to call in to the triage line or present to a health care facility to be evaluated. Thus, the research team will compare Unplanned Healthcare Utilization, i.e. the frequency of triage calls, MyChart messages, Urgent Care visits, and Emergency Department visits related to urinary symptoms, between participants in the self-start intervention group and those in the triage control group. The team hypothesizes that patients in the \"self-start\" intervention group will demonstrate a lower frequency of healthcare utilization events when compared to those in the standard of care control.",[27],{"date":88,"type":37},"2026-06-25",{"date":90,"type":21},"2026-07-01",{"date":92,"type":21},"2028-03-31",{"name":94,"class":73},"The Cleveland Clinic",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":54,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100575251","phase-4-defining-the-safety-and-efficacy-of-posterior-tibial-nerve-stimulation-in-children-100575251","NCT06769854","Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children","POSITRON-C","Inclusion Criteria:\n\n1. Age 5-21 years old (inclusive)\n2. Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization from the participant or the participant's parent\u002Flegal guardian\u002Flegally authorized representative (LAR)\n3. Minor participant is willing and able to provide assent (as applicable)\n4. History of primary or secondary non-neurogenic OAB as defined by a VDES score of ≥11 and a positive modified bother score within 30 days of consent\n5. Has previously tried and failed standard urotherapy and at least one anticholinergic or beta-3 adrenergic agonist\n6. Adequate fluid intake for age as reported by participant or parent\u002Flegal guardian\u002FLAR\n7. Micturition frequency of at least 8 times (mean)\u002Fday for at least 4 weeks prior to enrollment\n8. At least 1 daytime incontinence episode (mean)\u002Fday for at least 4 weeks prior to enrollment\n9. If on allowed treatment for OAB, stable dose for at least 30 days prior to screening and willingness to continue that dose for the duration of the study\n\nExclusion Criteria:\n\n1. Known or apparent untreated anatomical abnormality of the lower urinary tract (e.g., untreated ureterocele)\n2. Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)\n3. Presence of local skin lesions (e.g., rash, skin infections) on the medial surfaces of both ankles at the time of consent\n4. Metal implants in the medial ankle area\n5. Pacemakers or implantable defibrillators\n6. History of excessive bleeding\n7. Nerve damage that may impact the percutaneous tibial nerve or pelvic floor function\n8. History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)\n9. Known current, untreated UTI\n10. Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential\n11. Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety\n12. Previous treatment with this device or participation in this study or in any other study for the treatment of OAB\n13. High-grade vesicoureteral reflux (grades 4-5)\n14. Diagnosed diabetes insipidus (pituitary, nephrogenic, or acquired)\n15. Stage 4-5 chronic kidney disease (CKD) (since device may further disrupt or exacerbate abnormal urine flow)\n16. Significant post-void residual defined as \\>60 mL\n17. Initiation of or change of OAB treatment during screening or the duration of the study.",true,"ALL","5 Years",{"count":106,"type":21},50,[108],"PHASE4","The purpose of this study is to find out if overactive bladder (OAB) can be safely treated by stimulating a nerve near the ankle. This procedure is called percutaneous tibial nerve stimulation (PTNS). It will be done by a device called the Urgent PC. The Urgent PC works by sending weak electrical signals through a thin needle to the nerve near the ankle. Stimulating this nerve may change bladder control.",[27,111],"Overactive Bladder Syndrome",[113,27,114,115,116,117,118,119,120,121,122,123,124],"PTNS","percutaneous tibial nerve stimulation","Urgent PC","urinary urgency","urinary incontinence","urinary frequency","OAB","urinary urge","Urinary Bladder","Urinary Bladder Diseases","Urologic Diseases","Pediatrics","2026-06-15",{"date":127,"type":37},"2026-06-17",{"date":129,"type":21},"2027-04-01",{"date":131,"type":21},"2029-10-31",{"name":133,"class":73},"Chi Dang Hornik",{"id":135,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":25,"conditions":138,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":144},"100555365",{"count":20,"type":21},[24],[27,28,29,30,31,32],"2026-06-11",{"date":125,"type":37},{"date":39,"type":37},{"date":41,"type":21},{"name":43,"class":44},20,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":74},"100506789","phase-2-examining-the-effects-of-intra-detrusor-botox-at-time-of-holep-in-men-with-overactive-bladder-symptoms-100506789","NCT05878951","Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms","A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms","Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Component of OAB symptoms including frequency, nocturia, urgency, and\u002For urge related incontinence\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to OnabotulinumtoxinA injections\n* Patients having a concurrent ureteroscopy +\u002F- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy\n* Patients who lack decisional capacity\n* Active urinary tract infection","89 Years",{"count":154,"type":21},66,[156,157],"PHASE2","PHASE3","The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",[160,111,27,123],"Urinary Incontinence","2026-06-02",{"date":163,"type":37},"2026-06-04",{"date":165,"type":37},"2023-07-13",{"date":167,"type":21},"2026-12-31",{"name":169,"class":73},"Northwestern University",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":74},"100626209","add-on-zida-sock-therapy-for-overactive-bladder-100626209","NCT07432659","Add-On ZIDA Sock Therapy for Overactive Bladder","Add-On Efficacy of Home-Based Transcutaneous Tibial Nerve Stimulation Via the ZIDA Control Sock in Adults With Overactive Bladder on Preexisting Stable Pharmacotherapy","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of OAB-wet (OAB with urgency urinary incontinence) documented by clinical diagnosis\n* Baseline ≥1 UUI episode\u002Fday averaged over a 3-day diary\n* Is on a stable pharmacotherapy for OAB for ≥4 weeks, with intent to remain on their medication regimen for the duration of this study\n* Has the ability to complete bladder diaries, questionnaires, and attend follow-up visits\n* Cognitively intact adult and able to understand study procedures and provide informed consent independently\n\nExclusion Criteria:\n\n* Neurologic disease affecting bladder function, including multiple sclerosis, spinal cord injury, Parkinson's disease, or other neurogenic bladder conditions.\n* Significant pelvic organ prolapses or other pelvic pathology likely to interfere with bladder emptying, neuromodulation efficacy, or study assessments in the opinion of the investigator\n* Active urinary tract infection or unexplained hematuria at screening\n* Clinically significant post-void residual volume above threshold (e.g., \\>100 mL)\n* History of, failure of, or current use of neuromodulation therapies, including percutaneous or transcutaneous tibial nerve stimulation, sacral neuromodulation (InterStim), implantable tibial devices (eCoin)\n* Intravesical botulinum toxin injections less than 9 months prior to entry into the study\n* Pregnancy or plans to become pregnant during study participation, and women of childbearing age not using contraception. A urine pregnancy test will be performed for women of childbearing potential to confirm non-pregnant status prior to enrollment.\n* Contraindications to electrical stimulation (cardiac pacemaker or implanted defibrillator without physician clearance, unhealed wounds near stimulation site, metal implants in the ankle region)\n* Significant uncontrolled medical conditions, such as unstable cardiac disease, poorly controlled diabetes mellitus, severe peripheral edema, or severe peripheral neuropathy that may affect lower-limb sensation or response to stimulation in the opinion of the investigator\n* Pelvic malignancy or prior pelvic radiotherapy.\n* Current participation in another investigational drug or device trial, or use of an investigational therapy within the last 30 days\n* Known hypersensitivity or intolerance to materials used in the ZIDA device (electrode adhesives, conductive gels)",{"count":144,"type":21},[24],"Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild electrical stimulation near the ankle, as an adjunct to usual care. Adults with OAB-wet who remain symptomatic on stable medication will use the device at home once weekly for 12 weeks while continuing their prescribed therapy. The study collects clinical, patient-reported, and safety information during adjunctive device use.",[27],[27,182,183,184,185,186],"Urgency Urinary Incontinence","Transcutaneous Tibial Nerve Stimulation","TTNS","Neuromodulation","ZIDA Control Sock","2026-05-05",{"date":189,"type":37},"2026-05-06",{"date":191,"type":37},"2026-04-17",{"date":193,"type":21},"2028-03",{"name":195,"class":73},"Medical University of South Carolina",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":103,"minAge":104,"maxAge":18,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":74},"100531531","vitamin-d-treat-to-target-strategy-for-children-with-overactive-bladder-wet-100531531","NCT06201013","Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet","Efficacy, Neural Repair Mechanism, and Health Economics of a Multimodal Treat-to-Target Strategy Incorporating Vitamin D for Pediatric Overactive Bladder-Wet: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children older than or equal to 5 years of age with a diagnosis of wet OAB (the diagnosis followed the latest guidelines of ICCS) attending the outpatient clinic of the Department of Urology of the Affiliated Children's Hospital of Chongqing Medical University,\n* children with serum vitamin D levels below 35 ng\u002Fml as indicated by the tests conducted by the hospital\n* children whose guardians have given their informed consent, are able to ensure compliance and have signed a paper-based informed consent form.\n\nExclusion Criteria:\n\n* Those with urinary malformations or serious diseases (e.g., hypospadias, cryptorchidism, posterior urethral valvulae, vesicoureteral reflux, neurogenic bladder, urinary tumors, urinary stones, bladder and urethral injuries, etc.)\n* Those with neurological disorders (e.g., epilepsy, spinal cord injuries, spinal dysplasia, spinal embolism syndrome, multiple sclerosis, and autism spectrum disorders, etc.)\n* People with serious heart disease, abnormal liver and kidney function, lung disease, bone deformity, serious digestive tract disease, genetic metabolic disease\n* People with history of gastrointestinal surgery and urological surgery\n* People with dry stools and long-term constipation\n* People who are taking anticonvulsant and antiepileptic drugs, hormones, and anti-tuberculosis drugs\n* People with history of hypercalcemia, hyperphosphatemia with renal rickets\n* People who have had unexplained hematuria and hematuria with renal rickets within the last year\n* People who have been suffering from severe heart disease or chronic diabetes.\n* participation in other clinical studies at the time of consultation or during the follow-up period of other clinical studies\n* unwillingness to participate in this study",{"count":204,"type":21},180,[24],"The purpose of this clinical trial is to investigate whether adding high-dose vitamin D (2,400 IU daily) to standard medical treatment (solifenacin combined with behavioral therapy) is more effective than standard treatment alone for children with overactive bladder-wet (OAB-wet).\n\nOAB-wet causes sudden urinary urges and frequent daytime or incontinence, which significantly impacts a child's quality of life and increases the family's caregiving burden. While solifenacin is a standard medication used to calm the bladder, many children do not achieve complete dryness. This study introduces the \"Treat-to-Target\" (T2T) approach, where clinicians and families set personalized \"functional goals\" (such as zero leakage) and monitor progress closely to adjust care.\n\nThe study aims to answer the following questions:\n\nDoes adding vitamin D help more children achieve their goal of \"zero leakage\" compared to standard treatment? Does vitamin D help repair bladder-related nerves, as measured by a specific marker in the urine? Does this combined approach reduce the family's expenses (like laundry costs and diaper use) and improve the child's self-esteem?\n\nParticipants will be randomly assigned to one of two groups for 12 weeks:\n\nIntervention Group: Standard care (solifenacin + behavioral therapy) plus daily vitamin D (2,400 IU).\n\nControl Group: Standard care (solifenacin + behavioral therapy) alone. Researchers will evaluate symptoms, vitamin D levels, and nerve repair markers at 6 and 12 weeks to determine the best treatment strategy for these children.",[208,27,209],"Urinary Bladder, Overactive","Urinary Incontinence, Urge",[208,209,211],"Vitamin D","2026-04-14",{"date":191,"type":37},{"date":215,"type":21},"2026-04-20",{"date":217,"type":21},"2027-04-15",{"name":219,"class":73},"Children's Hospital of Chongqing Medical University",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":244},"100607354","phase-4-behavioral-andor-mirabegron-to-treat-urinary-symptoms-in-parkinson-disease-100607354","NCT07187466","Behavioral and\u002For Mirabegron to Treat Urinary Symptoms in Parkinson Disease","Sequential Multiple Assignment Randomized Trial to Treat Urinary Symptoms in Parkinson Disease","SQUARE PD","Inclusion Criteria:\n\n* Clinical diagnosis of PD determined by a board-certified neurologist with specialty training in movement disorders\n* An ICIQ-OAB Symptom Score of 7 or higher, which indicates clinically significant symptoms of OAB, defined as presence of urinary urgency with or without urgency incontinence usually with increased daytime frequency and nocturia in the absence of infection or other obvious pathology\n\nExclusion Criteria:\n\n* Significant cognitive impairment, as indicated by a Montreal Cognitive Assessment (MoCA) score of \\\u003C 18 or a telephone-MoCA score \\\u003C 13, which is the recommended diagnostic cut point for dementia in PD.\n* Previous intensive pelvic floor muscle exercise training\n* Clinically significant depression as measured by a Geriatric Depression Scale-Short Form score of 10 or higher which could affect motivation to fully engage in the intervention\n* Use of an indwelling urinary catheter\n* Post-void residual urine measurement by bladder ultrasound of \\> 150 mL\n* Severe uterine prolapse past the vaginal introitus\n* Poorly controlled diabetes defined by a hemoglobin A1c (HgbA1c) of \\>9.0% within the last 3 months. Participants with poorly controlled diabetes will be offered enrollment if the OAB symptoms persist after improvement in diabetes control\n* Chronic renal failure and on hemodialysis\n* Genitourinary cancer with ongoing surgical or external beam radiation treatment\n* Previous artificial urinary sphincter, sling procedure or implanted sacral neuromodulation device\n* History of bladder-injection of botulinum toxin in the last 12 months\n* Any unstable health condition expected to result in hospitalization or death within in the next 3 months as determined by principal investigator.\n* Hypersensitivity to drug class\n* Contraindication to the study drug (mirabegron) including history of acute urinary retention requiring catheterization\n* Current use of a bladder relaxant - permitted to enroll after one-week washout\n* Hematuria on microscopic examination in the absence of infection. A urologic consultation will be recommended, and enrollment will depend on clearance by a urologist and agreement by the site PI that entry into the treatment protocol is not contraindicated\n* If on diuretic, dose should be stable for at least 4 weeks\n* If taking an alpha-blocker, dose should be stable for at least 4 weeks\n* If taking dutasteride or finasteride, dose should be stable for at least 6 months",{"count":229,"type":21},146,[108],"The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug treatment) will respond to combined treatment. The investigators also want to find out what factors influence whether someone responds to the treatments.",[27,233],"Parkinson Disease",[208,233],"2026-04-03",{"date":237,"type":37},"2026-04-06",{"date":90,"type":21},{"date":240,"type":21},"2030-06-30",{"name":242,"class":243},"VA Office of Research and Development","FED",3,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":102,"sex":103,"minAge":4,"maxAge":18,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":74},"100632413","the-role-of-urinary-rhoa-ngf-and-bdnf-levels-in-overactive-bladder-and-vitamin-d-deficiency-100632413","NCT07513363","The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency","The Role of Urinary RhoA, NGF, and BDNF Levels in Diagnosis and Follow-up in Children With Overactive Bladder and Vitamin D Deficiency.","Inclusion Criteria:\n\n* Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)\n\nExclusion Criteria:\n\n* Neurological diseases\n* Malignancy\n* Active urinary tract infections\n* Anatomical bladder anomalies\n* History of prior OAB treatment\u002Furological surgery.",{"count":253,"type":21},52,[24],"The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.",[27,257],"Vitamin D Deficiency","2026-04-01",{"date":260,"type":37},"2026-04-07",{"date":262,"type":21},"2026-05-01",{"date":264,"type":21},"2027-01-01",{"name":266,"class":73},"Tarik Emre Sener",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":74},"100489354","noninvasive-ultrasound-assessment-of-detrusor-dysfunction-100489354","NCT05652023","Noninvasive Ultrasound Assessment of Detrusor Dysfunction","NUADD","Inclusion Criteria:\n\n* Aim1:\n\nAge \\>18 scheduled to undergo UDS for their clinical care for one of the included diagnoses.\n\n-Aim2: Inclusions: Age \\>45 scheduled to undergo selective photovaporization of the prostate.\n\nExclusion Criteria:\n\n* Aim1:Obesity (BMI \\>35kg\u002Fm2), known neurologic disease impacting bladder function (e.g. spinal cord injury, multiple sclerosis, Parkinson's, prior cerebrovascular accident), previous pelvic radiation therapy, previous radical pelvic surgery (such as for uterine or colorectal cancer), prior bladder surgery (including prostate resection), and pregnant or breast-feeding women.\n* Aim2:Obesity (BMI \\>35kg\u002Fm2), known neurologic disease impacting bladder function (e.g. spinal cord injury, multiple sclerosis, Parkinson's, prior cerebrovascular accident), previous pelvic radiation therapy, previous radical pelvic surgery (such as colorectal cancer).","90 Years",{"count":276,"type":21},2023,"OBSERVATIONAL","The purpose of this study is to test a new ultrasound method called Quantitative Ultrasound Bladder Vibrometry to detect abnormal bladder function.",[280,27,281],"Bladder Dysfunction","BPH With Urinary Obstruction",[283,284,285,286],"Detrusor Pressure","Bladder Compliance","Ultrasound","Ultrasound Vibrometery","2026-03-23",{"date":289,"type":37},"2026-03-27",{"date":291,"type":37},"2023-04-20",{"date":293,"type":21},"2028-12-20",{"name":72,"class":73},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":74},"100521677","neuromodulating-cortical-regions-involved-in-neurogenic-bladder-in-ms-100521677","NCT06072703","Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS","A Randomized, Sham-Controlled Clinical Trial Evaluating Individualized Neuromodulation of Cortical Regions Involved in Neurogenic Overactive Bladder in Multiple Sclerosis","MSBLADDER","Inclusion Criteria:\n\n* Adult women (≥ 18 years of age)\n* Clinically stable MS defined as ExpandedDisability Status Score (EDSS) ≤ 7.5without exacerbation worsening in the preceding 6 months prior to study entry\n* Neurogenic Lower Urinary Tract Dysfunction symptoms ≥ 3 months with NBSS total ≥ 15\n* Individuals with Montreal Cognitive Assessment (MoCA) score \\>10 will be eligible\n* At least one bladder storage symptoms (e.g., urinary frequency, urinary urgency, nocturia with or without incontinence) indicated by OAB -AT≥ 8\n* Individuals with active urinary tract infection (UTI) will be treated and will be enrolled after negative urinalysis\n\nExclusion Criteria:\n\n* Pregnant\u002Fplanning to become pregnant or nursing\n* Urodynamic findings of bladder outlet obstruction\n* Baclofen or other intrathecal pumps, Pacemakers.\n* History of seizure disorder (SZ), immediate family of SZ disorder, in addition to individuals who are taking any medications such as (bupropion) Wellbutrin or substances (ex: heavy alcohol use) that would lower seizure threshold will be excluded.\n* History of bipolar disorder, or individuals who are taking medications that can exacerbate the condition such as tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-nor-epinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion (Wellbutrin) and antihistamines will be excluded.\n* All intracranial lesions and hemorrhagic stroke will be excluded\n* History of moderate to severe heart disease or unstable angina\n* History of Autonomic Dysreflexia\n* History of interstitial cystitis, pelvic radiation\n* Intra-detrusor botulinumtoxinA (BTX-A) injection over the past 6 months\n* Incarcerated patients will be excluded.\n* Active sacral nerve stimulation (SNS) device or any other spinal stimulators\n* Indwelling urethral or suprapubic catheter",{"count":304,"type":21},29,[24],"Neurogenic overactive bladder (NOAB), characterized by urinary frequency, urgency or urgency incontinence symptoms occurring during the storage phase of the bladder, is the most common urinary complaint in multiple sclerosis (MS). Current management options for NOAB in MS have limited efficacy and considerable adverse effects, which underscores the significance of this study and highlights the need for better, less invasive therapies. This novel study investigates brain therapeutic targets that could shift the focus of NOAB management in MS from a bladder-centric focus to brain restoration; specifically modulating the brain regions identified in the prior functional magnetic resonance imagining studies. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation that can modulate neurons (excite or inhibit) to improve the connectivity of the regions of interest (ROI). The preliminary data demonstrate, for the first time, significant improvement in bladder symptoms in ten women with MS who have voiding dysfunction following multifocal transcranial magnetic stimulation without any treatment-related adverse effects.\n\nThis randomized double-blind, sham-controlled single center clinical trial with an optional open-label extension (OLE) phase is designed to evaluate the effects of targeted rTMS in women with MS and NOAB by investigating restorative reorganization of brain function The main purpose of this study is to determine the effects of individualized repetitive Transcranial Magnetic Stimulation (rTMS) for improving overactive bladder symptoms such as urinary frequency and urgency with or without incontinence in individuals with multiple sclerosis (MS). Patients will undergo initial screening that includes a demographics information, physical exam, past medical and surgical history, medication list, urine pregnancy test (female subjects with childbearing potential), and completion of questionnaires to confirm the eligibility of patients. All eligible patients will be required to complete a functional MRI scan followed by locating the regions of interest through neural navigation system and finally receiving 10 treatment sessions.\n\nSince this is a randomized trial, some patients will receive active treatment\u002F therapy sessions while others will only receive sham or placebo treatments. The total duration to complete all treatment sessions and follow up visits is approximately 4-5 months.",[308,309,27],"Neurogenic Bladder","Multiple Sclerosis",[311,312,313,185],"Neurogenic bladder","Functional Neuroimaging","repetitive Transcranial Magnetic Stimulation (rTMS)","2026-03-18",{"date":287,"type":37},{"date":317,"type":37},"2023-10-30",{"date":319,"type":21},"2027-12-31",{"name":321,"class":73},"The Methodist Hospital Research Institute",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":74},"100498621","clinical-and-urodynamic-assessment-of-bladder-sensation-in-multiple-sclerosis-100498621","NCT05772637","Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis","CUBS-MS","Inclusion Criteria:\n\n* Age ≥ 18\n* MS according to the 2017 Mac Donald diagnostic criteria\n* Bladder disorders supposedly related to MS\n* Indication to perform urodynamics\n* No current medication for bladder disorders\n* Able to understand and right in French\n* Affiliated to the \"Securite sociale\" or \"Couverture Medicale Universelle (CMU)\", or equivalent organism.\n\nExclusion criteria:\n\n* Legal protection\n* Pregnancy or breastfeeding mother\n* MS relapse during the past month\n* Other associated neurological disease\n* Genuine stress incontinence related to postpartum\n* Treatment with antimuscarinics, alpha blockers, beta3 adrenergic, or tibial nerve stimulation in the past 15 days, or with botulinic toxin injection in the past 6 months\n* Previous lower urinary tract surgery\n* Inability to use the analogic device due to motor, sensory or ataxic disabilities","99 Years",{"count":331,"type":21},113,[24],"The aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of Overactive bladder (OAB) in patients with multiple sclerosis.",[27],[336,337,338],"overactive bladder","multiple sclerosis","bladder sensations","2026-03-04",{"date":341,"type":37},"2026-03-05",{"date":343,"type":37},"2024-02-14",{"date":345,"type":21},"2027-02-14",{"name":347,"class":73},"Assistance Publique - Hôpitaux de Paris",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":102,"sex":53,"minAge":356,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":373},"100467095","phase-4-treating-incontinence-for-underlying-mental-and-physical-health-100467095","NCT05362292","TReating Incontinence for Underlying Mental and Physical Health","Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence","TRIUMPH","Inclusion Criteria:\n\n* Aged 60 years or older at the time of enrollment\n* Female sex at birth, without surgical or hormonal gender re-assignment therapy\n* Able to walk to the bathroom and use the toilet without assistance\n* Report urinary incontinence starting at least 3 months prior to screening\n* Report that at least half of incontinence episodes occur with a sudden or strong sensation of urgency\n* Report 2 or more urgency incontinence episodes over a 7-day period\n* Willing to provide informed consent and adhere to study procedures throughout the length of the study\n\nExclusion Criteria:\n\n* Prior clinician diagnosis of dementia, or a Montreal Cognitive Assessment (MOCA) score of 17 or lower on screening cognitive evaluation\n* Current use of anticholinergic, beta-3-adrenergic agonist, or other medication designed to improve urgency incontinence symptoms, or use in the past 1 month\n* Initiation, discontinuation, or dose change of dementia medications (such as donepezil, galantamine, memantine, rivastigmine) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs with strong anticholinergic effects (based on the Beers List) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs that can affect urinary frequency, including diuretics, in the past 1 month (but candidates on stable doses are eligible)\n* Current urinary tract infection (UTI) based on screening urinalysis and culture (but candidates can re-present for re-screening after undergoing treatment for UTI)\n* History of allergy or sensitivity to either of the study medications or an ingredient in the placebo or study medication capsule\n* Severe hepatic impairment (Child-Pugh score B or greater) or renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin) as a contraindication to both study medications\n* Current bladder obstruction or urinary retention (defined by symptoms suggesting difficulty emptying the bladder in addition to postvoid residual urine volume greater than 150 cc by portable bladder ultrasound)\n* Uncontrolled hypertension (based on measured systolic blood pressure greater than 180 or diastolic blood pressure greater than 110 mmHg) as a contraindication to beta-3-adrenergic therapy\n* Self-reported history of gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, or toxic megacolon as contraindications for anticholinergic bladder therapy\n* Use of drugs with adverse interactions with one of the study medications in the past 1 month, including potent CYP3A4 inhibitors, hepatic enzyme metabolism inducers, narrow therapeutic index drugs metabolized by CYP2D6, or intention to start taking one of these medications during the study treatment period\n* History of bladder surgery, invasive intra-vesical therapy, or bulk bladder injections in the past 3 months (more remote surgery will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Use of other specialized incontinence therapy (electrostimulation, pelvic physiotherapy, formal behavioral therapy overseen by certified practitioners) in the past 3 months (more remote therapy will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Inability to sign informed consent or complete questionnaires, interviews, or study testing in English\n* Other condition that would prevent the participant from completing study procedures, in the opinion of the investigators (e.g., uncontrolled psychosis)","60 Years",{"count":358,"type":21},270,[108],"The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.",[209,160,27,362,363,364],"Incontinence, Urge","Incontinence, Urinary","Incontinence",{"date":366,"type":37},"2026-03-06",{"date":368,"type":37},"2022-10-04",{"date":370,"type":21},"2027-08-02",{"name":372,"class":73},"University of California, San Francisco",2,{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":152,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":388,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":74},"100402988","fluoroscopy-radiation-reduction-during-sacral-neuromodulation-lead-placement-100402988","NCT04527445","Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement","Reduction in Fluoroscopy Radiation Exposure During Lead Implantation for Sacral Neuromodulation: A Randomized Prospective Study","Inclusion Criteria:\n\n* Patients undergoing lead implantation for sacral neuromodulation that have overactive bladder as defined by urinary urgency, frequency, nocturia with or without urgency incontinence.\n\nExclusion Criteria:\n\n* neurogenic bladder, BMI \\>40, or peripheral neuropathy.",{"count":56,"type":21},[24],"Fluoroscopy is performed when placing a lead during a sacral neuromodulation procedure. During lead placement, subjects will receive either conventional or experimental fluoroscopic settings. The radiation exposure will be compared between the two groups.",[385,27,386,387],"Radiation Exposure","Urge Incontinence","Urgency-frequency Syndrome",[389,390],"Sacral Neuromodulation","Fluoroscopy",{"date":366,"type":37},{"date":393,"type":21},"2026-06",{"date":395,"type":21},"2027-06",{"name":397,"class":73},"Loma Linda University",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":421},"100454698","pelvic-health-electrically-evoked-recording-peer-2-study-100454698","NCT05200923","Pelvic Health Electrically Evoked Recording (PEER) 2 Study","PEER 2","Inclusion Criteria:\n\nOveractive Bladder Criteria Inclusion Criteria\n\n1. 18 years of age or older\n2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\\* requiring an advanced evaluation\n3. Willing and able to provide signed and dated informed consent\n4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol\n5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation\n6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.\n7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.\n\nNote\\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.\n\nNon-Obstructive Urinary Retention Inclusion Criteria\n\n1. 18 years of age or older\n2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\\* requiring an advanced evaluation\n3. Willing and able to provide signed and dated informed consent\n4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol\n5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation\n6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.\n\nNote\\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.\n\nFecal Incontinence Inclusion Criteria\n\n1. 18 years of age or older\n2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication\\* requiring an advanced evaluation\n3. Willing and able to provide signed and dated informed consent\n4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol\n5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation\n6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling)\n\nNote\\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.\n\nExclusion Criteria:\n\nOveractive Bladder Criteria Exclusion Criteria\n\n1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)\n2. Implanted with a neurostimulator, pacemaker or defibrillator\n3. Pelvic floor muscle dysfunction due to surgical intervention or injury\n4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)\n5. History of diabetes unless the diabetes is well-controlled through diet and\u002For medications\n6. Have symptomatic urinary tract infection (UTI)\n7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component\n8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study\n9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months\n10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study\n11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy\n12. Women who are pregnant or planning to become pregnant\n13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)\n14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements\n\nNon-Obstructive Urinary Retention Exclusion Criteria\n\n1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)\n2. Implanted with a neurostimulator, pacemaker or defibrillator\n3. Pelvic floor muscle dysfunction due to surgical intervention or injury\n4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)\n5. History of diabetes unless the diabetes is well-controlled through diet and\u002For medications\n6. Have symptomatic urinary tract infection (UTI)\n7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months\n8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study\n9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy\n10. Women who are pregnant or planning to become pregnant\n11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)\n12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements\n\nFecal Incontinence Exclusion Criteria\n\n1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)\n2. Implanted with a neurostimulator, pacemaker or defibrillator\n3. Pelvic floor muscle dysfunction due to surgical intervention or injury\n4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)\n5. Have uncorrected high grade internal rectal prolapse\n6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months\n7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study\n8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy\n9. Women who are pregnant or planning to become pregnant\n10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements",{"count":406,"type":21},300,[24],"To collect physiological signals at several timepoints during the therapy evaluation period.",[27,410,411],"Fecal Incontinence","Urinary Retention","2026-03-02",{"date":414,"type":37},"2026-03-03",{"date":416,"type":37},"2022-01-18",{"date":418,"type":21},"2026-12-18",{"name":420,"class":44},"MedtronicNeuro",7,{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":102,"sex":53,"minAge":18,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":74},"100627758","turkish-usiq-validity--reliability-100627758","NCT07452796","Turkish USIQ: Validity & Reliability","Validity and Reliability of the Turkish Version of the Urgency, Severity, and Impact Questionnaire (USIQ)","Inclusion Criteria:\n\n* Women aged 18-65 years\n* Able to read and write in Turkish\n* Diagnosed with overactive bladder (OAB) presenting with urgency (either wet or dry type)\n* Willing to sign the informed consent form after being informed about the study\n\nExclusion Criteria:\n\n* Urinary tract infection symptoms or an active infection diagnosis within the past month\n* Neurological conditions causing neurogenic bladder such as multiple sclerosis, Parkinson's disease, stroke, or spinal cord injury\n* Cognitive impairment preventing comprehension and completion of the questionnaires\n* Post-void residual urine volume (PVR) exceeding 150 mL\n* History of bladder stones, bladder tumors, or recent major urogenital surgery\n* Pregnancy or suspected pregnancy","65 Years",{"count":431,"type":21},130,"The Urgency, Severity, and Impact Questionnaire (USIQ) assesses urinary urgency independently of incontinence, measuring both symptom severity and its impact on quality of life. While validated in English and Hebrew populations, a Turkish version has not yet been developed. This study aims to adapt USIQ for the Turkish population and evaluate its psychometric properties, providing a standardized, culturally relevant tool for clinical and research use.",[27],[435,160,436],"Urinary Urgency","Validation Studies","2026-03-01",{"date":341,"type":37},{"date":440,"type":21},"2026-04-15",{"date":442,"type":21},"2027-11-15",{"name":444,"class":73},"Izmir Democracy University",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":74},"100625984","phase-3-efficacy-of-gabapentin-combined-with-solifenacin-for-non-neurogenic-overactive-bladder-in-women-100625984","NCT07429734","Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women","Efficacy and Tolerability of Solifenacin Combined With Gabapentin Versus Solifenacin Monotherapy for the Treatment of Non-neurogenic Overactive Bladder in Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Overactive bladder symptom score (OABSS) \\> 5, urgency subscore ≥3, and urge incontinence score≥ 2.\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Neurogenic bladder\n* History of genitourinary malignancy\n* Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI\n* Any psychological or psychiatric disorders",{"count":453,"type":21},60,[157],"The goal of the study is to compare the efficacy, safety and tolerability of solifenacin plus gabapentin versus solifenacin monotherapy for the treatment of women who are suffering from non-neurogenic ОАВ.\n\nThe main questions it aims to answer are:\n\nDoes combination of Solifenacin and Gabapentin affect the total score and sub-scores of OABSS in females with non-neurogenic ОАВ ? What medical problems do participants have when taking combination of Solifenacin and gabapentin ?",[27],[336,458,459,460,461,462],"non-neurogenic","gabapentin","solifenacin","anticholinergic","Randomized Controlled Trial","2026-02-23",{"date":465,"type":37},"2026-02-24",{"date":467,"type":21},"2026-02",{"date":469,"type":21},"2027-01",{"name":471,"class":73},"Mansoura University",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":103,"minAge":479,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":490,"leadSponsor":492,"locationsCount":74},"100616414","mirabegron-in-patients-with-age-related-macular-degeneration-100616414","NCT07305298","Mirabegron in Patients With Age-Related Macular Degeneration","Mirabegron in Patients With Age-Related Macular Degeneration Treated for Overactive Bladder: A Study Protocol for a Non-Randomized Prospective Controlled Trial","Inclusion Criteria:\n\n* Age subjects 50 and 80 years-old\n* Ability to express informed consent\n* Early or moderate dry AMD according to ARDS classification\n* Overreactive bladder\n* Visual acuity greater than BCVA 65 EDTRS letters.\n\nExclusion Criteria:\n\n* • Any medical condition which contraindicates the use of beta-agonists\n\n  * Uncontrolled hypertension\n  * Tachycardia or atrial fibrillation\n  * Any allergies to the beta-agonists\n  * Renal or hepatic failure\n  * Long QT or concomitant treatment with drugs that cause lengthening of the QT interval\n  * Any sign of ocular inflammation\n  * xudative AMD\n  * Any ongoing medical or surgical treatment for AMD (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)\n  * Any other ophthalmic diseases such glaucoma, acute or chronic uveitis, advanced cataract, or any opacities of the ocular media that do not permit high-quality imaging examinations.\n  * Pregnancy\n  * Any condition or disease that in the opinion of the investigators may put the subject at significant risk or may interfere significantly with the subject's participation in the study (i. e. malignancy, uncontrolled or cardiovascular diseases)","50 Years","80 Years",{"count":482,"type":21},312,"The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.\n\nThe main question it aims to answer is:\n\n• Is there any change in outer retina morphology in patients treated?\n\nResearchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.\n\nParticipants will:\n\n* Take Mirabegron or Solifenacin every day for 12 months\n* Visit the clinic once every 6 months for checkups and tests",[485,27],"Dry AMD","2026-02-04",{"date":488,"type":37},"2026-02-06",{"date":258,"type":21},{"date":491,"type":21},"2026-12-01",{"name":493,"class":73},"University of Naples",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":102,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":74},"100533469","percutaneous-nerve-evaluation-trial-time-100533469","NCT06226220","Percutaneous Nerve Evaluation Trial Time","Trial Time for Percutaneous Nerve Evaluation in Patients Undergoing Sacral Neuromodulation for Urgency Urinary Incontinence or Urgency-frequency: a Randomized Control Trial","Inclusion Criteria:\n\n* Non-pregnant women \\>\u002F=18 years old undergoing sacral neuromodulation (SNM) treatment for urgency urinary incontinence (UUI) or urgency-frequency (UF) who have elected to undergo testing phase with a PNE\n* \\>\u002F=5 UUI episodes on a 3-day bladder diary with urge incontinence representing \\>\u002F=50% of total incontinence episodes recorded or \\>\u002F=8 per day for 2 days on a 3-day bladder diary\n* Willing and able to complete all study related items and interviews\n* Grossly neurologically normal exam\n\nExclusion Criteria:\n\n* SNM indication of non-obstructive urinary retention or isolated fecal incontinence\n* Severe or poorly controlled diabetes (defined as HgbA1c \\>\u002F=8.0) or diabetes with peripheral nerve involvement\n* Neurological diseases such as multiple sclerosis, clinically significant peripheral neuropathy, or complete spinal cord injury\n* Surgically altered detrusor muscle (i.e. Augmentation cystoplasty)\n* Current or prior bladder malignancy\n* Prior pelvic irradiation\n* Post void residual (PVR) \\>\u002F= 150 mL within 6 months prior to enrollment\n* Active urinary tract infection\n* Primary stress urinary incontinence or mixed urinary incontinence with stress predominance\n* \\>\u002F= Stage III pelvic organ or vaginal vault prolapse and\u002For current pessary use",{"count":502,"type":21},193,[24],"Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a percutaneous nerve evaluation (PNE) or a stage implantation. Patients who experience a \\> 50% improvement in UUI symptoms progress to permanent implantation. PNE offers significant advantages compared to a staged implantation including a single anesthetic and operating room trip. Historically, full implantation rates are only 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation after PNE may be attributed to lead migration. Newer data suggest up to 90% of PNE trials lead to full implantation. The investigators hypothesize that shortening PNE trial time to 3 days from 7 days will not result in a lower proportion of PNE trials leading to SNM implantation and may offer less time for lead migration. The investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to SNM implantation.",[386,387,27],[116,117,118,336,507,508],"sacral neuromodulation","percutaneous nerve evaluation",{"date":510,"type":37},"2026-02-09",{"date":512,"type":37},"2023-12-10",{"date":167,"type":21},{"name":515,"class":73},"University of Chicago",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":103,"minAge":522,"maxAge":18,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":74},"100508026","yoga-for-treatment-of-overactive-bladder-in-pediatric-patients-100508026","NCT05895045","Yoga for Treatment of Overactive Bladder in Pediatric Patients","Inclusion Criteria:\n\n* 8-18 years of age\n* History of non-neurogenic overactive bladder or detrusor overactivity and\u002For urinary incontinence (ICD 10 codes respectively - N32.81, N39.498)\n* Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent\u002Flegal guardian\n* Minor participant is willing and able to provide assent (as applicable)\n* Vancouver Dysfunctional Elimination Syndrome\\[15\\] score of ≥11 and a positive modified bother score within 30 days of consent\n\nExclusion Criteria:\n\n* Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele)\n* Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)\n* Nerve damage that may impact pelvic floor function\n* History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)\n* Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable)\n* Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential\n* Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety","8 Years",{"count":524,"type":21},40,[24],"The goal of this pilot study is to assess the impact of yoga as a treatment modality in pediatric patients age 8-18 diagnosed with idiopathic overactive bladder as measured by validated questionnaires and urinary biomarkers. The main question it aims to answer is: Does yoga help improve overactive bladder symptoms in this patient population? Participants will take part in a weekly yoga session for a total of 6 weeks with validated questionnaires and urinary samples for biomarkers to be completed at the beginning, middle and end of the study. This study will follow a cross-over study design and patients will receive standard of care while not in the active treatment arm.",[27,111,528],"Overactive Detrusor",[530,531,532,533],"bladder","overactive","detrusor","pediatric","2026-01-29",{"date":536,"type":37},"2026-01-30",{"date":538,"type":37},"2026-01-01",{"date":167,"type":21},{"name":541,"class":73},"Duke University",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":551,"briefSummary":552,"conditions":553,"keywords":558,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":573,"leadSponsor":575,"locationsCount":373},"100622722","phase-4-a-randomized-placebo-controlled-trial-of-nitrous-oxide-during-in-office-bladder-botox-injections-100622722","NCT07387315","A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","A Randomized, Placebo Controlled Trial of Nitrous Oxide\u002FOxygen Plus Standard Care Versus Standard Care Alone During In-office Intradetrusor onabotulinumtoxinA (Botox) Injections","Inclusion Criteria:\n\n* Adult women ≥18 years old scheduled for in-office intradetrusor botulinum toxin injection and able to consent.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected vitamin B12 or folate deficiency or high-risk state (e.g., pernicious anemia, malabsorption, post-bariatric or strict vegan without supplementation)\n* currently pregnant\n* severe\u002Funstable pulmonary disease or baseline hypoxemia requiring supplemental home oxygen\n* eye or ear surgery in the last six weeks\n* trapped-air conditions (e.g., untreated pneumothorax, bowel obstruction)\n* severe active otitis\u002Fsinus disease\n* inability to follow directions\n* history of adverse reaction to nitrous oxide",{"count":550,"type":21},96,[108],"The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure?\n\nResearchers will compare a 50:50 nitrous oxide\u002Foxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain.\n\nParticipants will:\n\n* Receive their bladder Botox injection in the office setting\n* Either use nitrous oxide\u002Foxygen plus standard care during the procedure, or sham mask plus standard care\n* Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure",[27,308,386,554,160,208,555,556,209,557],"Pain","Urinary Bladder, Neurogenic","Urinary Bladder Neurogenesis","Pelvic Floor Disorders",[27,160,386,559,560,561,562,563,564,565,566,567,568,569],"Intradetrusor Injection","OnabotulinumtoxinA","Botox","Bladder Botox","Botulinum Toxins, Type A","Pain Management","Analgesia","Nitrous Oxide","Office-based Procedures","Urogynecology","Pelvic Floor Disorder","2026-01-28",{"date":486,"type":37},{"date":467,"type":21},{"date":574,"type":21},"2026-12",{"name":576,"class":73},"TriHealth Inc.",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":53,"minAge":585,"maxAge":480,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":597,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":611},"100609041","detrusor-nerve-radiofrequency-ablation-for-overactive-bladder-in-women-100609041","NCT07209397","Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women","A Randomized, Prospective, Multicenter, Double-Blind, Sham-Controlled Study to Assess the MORPHEUSV Radiofrequency (RF) Device in the Treatment of Female Patients With Idiopathic Overactive Bladder (OAB) With Urge Incontinence and\u002For Urge-Predominant Mixed Incontinence","DENARA","INCLUSION CRITERIA:\n\n* Female, aged 22 to 80 years inclusive at the time of consent.\n* History of idiopathic overactive bladder (OAB) symptoms for ≥6 months.\n* At least 7 episodes of urge urinary incontinence (UUI) over 3 days, as recorded in a 3-day bladder diary during screening.\n* Urge-predominant incontinence, defined as greater number of UUI episodes than stress urinary incontinence (SUI) episodes during screening.\n* Willing and able to complete the 3-day bladder diary.\n* Willing to discontinue OAB medications (e.g., anticholinergics, beta-3 agonists) at least 2 weeks prior to baseline treatment visit, if currently taking such medications.\n* Willing to use a reliable method of contraception during the study period, if of childbearing potential and sexually active.\n* Negative pregnancy test at screening (if applicable).\n* Willing and able to provide written informed consent and comply with study procedures and follow-up schedule.\n\nEXCLUSION CRITERIA:\n\n* Predominant stress urinary incontinence (SUI) based on bladder diary\n* Currently pregnant, breastfeeding, or planning pregnancy during the study\n* History of neurologic conditions affecting bladder function (e.g., multiple sclerosis, spinal cord injury, Parkinson's disease)\n* Active urinary tract infection (UTI) at screening\n* History of interstitial cystitis, bladder pain syndrome, or chronic pelvic pain\n* Prior or current bladder cancer, pelvic malignancy, or pelvic radiation\n* Pelvic organ prolapse beyond the hymen (POP-Q stage \\> II)\n* Implanted neuromodulation device or prior sacral nerve stimulation\n* Use of bulking agents, Botox, or surgical treatment for incontinence within 12 months\n* Prior pelvic floor RF treatment or laser vaginal rejuvenation\n* Significant pelvic anatomical abnormalities that interfere with treatment\n* Use of investigational drug or device within 30 days before screening\n* Any condition that, in the investigator's opinion, would interfere with safe study participation or data integrity\n* Uncontrolled systemic disease (e.g., uncontrolled diabetes, cardiovascular disease)\n* Inability or unwillingness to comply with study requirements or follow-up","22 Years",{"count":587,"type":21},202,[24],"The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.",[27,591,592,593,594,595,596],"Overactive Bladder (OAB)","Urge Urinary Incontinence","Mixed Urinary Incontinence (Urge-Predominant)","Mixed Urinary Incontinence","Idiopathic Overactive Bladder With Urinary Incontinence","Idiopathic Overactive Bladder",[598,599,600,601,602,603],"Overactive bladder","Urge urinary incontinence","Mixed urinary incontinence","Female urinary symptoms","urogynecology","Female Urology",{"date":536,"type":37},{"date":606,"type":37},"2025-11-25",{"date":608,"type":21},"2027-11-30",{"name":610,"class":44},"InMode MD Ltd.",9,{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":631,"leadSponsor":633,"locationsCount":4},"100622111","bladder-overactivity-and-post-botulinum-toxin-telemonitoring-100622111","NCT07379372","Bladder Overactivity and Post-Botulinum Toxin Telemonitoring","Bladder Overactivity and Post-Botulinum Toxin Telemonitoring: a Randomized, Controlled, Superiority Trial","VESIC@HOME","Inclusion Criteria:\n\n* Patient with a neurogenic bladder or idiopathic overactive bladder.\n* Patient treated with intradetrusor botulinum toxin injection as part of their usual care, whether performing spontaneous voiding or self-catheterization.\n* Patient whose residence allows a home visit by a service provider within the area covered by the AGIR à dom group.\n* Patient affiliated with the social security system.\n* Patient willing to provide informed consent\n\nExclusion Criteria:\n\n* Persons covered under Articles L1121-5 to L1121-8 of the French Public Health Code (CSP), corresponding to all protected persons: pregnant or postpartum women, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, individuals admitted to a healthcare or social facility for purposes other than research, minors, persons under legal protection, or individuals unable to give consent.\n* Staff members with a hierarchical relationship with the principal investigator.",{"count":621,"type":21},112,[24],"Prospective, randomized, controlled, single-center study to compare the feasibility of home monitoring for patients receiving intradetrusor botulinum toxin injections with that of the usual hospital-based follow-up.",[27],[117,626,627],"botulinum toxin","connected urinary incontinence","2026-01-26",{"date":536,"type":37},{"date":412,"type":21},{"date":632,"type":21},"2031-03-02",{"name":634,"class":73},"University Hospital, Grenoble",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":103,"minAge":18,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":644,"briefSummary":645,"conditions":646,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":655},"100491922","a-real-world-study-of-ecoin-for-urgency-urinary-incontinence-post-approval-evaluation-recipe-100491922","NCT05685433","A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)","RECIPE","Inclusion Criteria:\n\n* Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population\n* Individual with diagnosis of overactive bladder with urgency urinary incontinence.\n* Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.\n* Individual gives written informed consent.\n* Individual is mentally competent and able to understand all study requirements.\n* Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.\n* Individual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to baseline or longer if the physician judges that the therapeutic effect is still present.\n* Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).\n* Individual is determined to be a suitable surgical candidate by physician.\n* Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.\n\nExclusion Criteria:\n\n* Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.\n* Individual has clinically significant bladder outlet obstruction. (Suspected bladder outlet obstruction will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has predominantly stress urinary incontinence (greater than 1\u002F3 of leaks on baseline diary are stress).\n* Individual has an active urinary tract infection at time of enrollment.\n* Individual has known polyuria.\n* Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome.\n* Individual has abnormal post void residual (i.e. greater than 200 cc initially and on repeat testing after double voiding)\n* Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.\n* Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.\n* Individual has had diagnosis of bladder, urethral, or prostate cancer.\n* Individual has had a prior anti-stress incontinence sling surgery within the last year.\n* Individual is pregnant or intends to become pregnant during the study.\n* Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.\n* Individual has uncontrolled diabetes mellitus (Hemoglobin A1C\\>7) or diabetes with significant peripheral complications. (Uncontrolled diabetes will be ruled out by blood test excluding those with Hemoglobin A1C\\>7).\n* Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator (ICD).\n* Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment, or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual has been treated with percutaneous tibial nerve stimulation (PTNS) within the previous 4 weeks prior to enrollment or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual is currently using transcutaneous electrical nerve stimulation (TENS) in the pelvic region, back, or legs.\n* Individual is aware that he or she will need an MRI scan other than a head\u002Fneck\u002Fshoulder MRI during the study period.\n* Individual has a clotting or bleeding disorder or is using anticoagulant therapies and in the opinion of the investigator is not a good candidate for the study (antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator).\n* Individual is neutropenic or immune-compromised.\n* Individual has had previous surgery and\u002For significant scarring at the implant location.\n* Individual has ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders.\n* Individual has a clinically significant peripheral neuropathy in the lower extremities.\n* Individual has neurogenic bladder dysfunction.\n* Individual has pitting edema at implant location (≥ 2+ is excluded).\n* Individual has inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.\n* Individual has varicose veins and is symptomatic.\n* Individual has open wounds, trauma, or prior surgery in the lower extremities.\n* Individual has arterial disease in the lower extremities.\n* Individual has vasculitis in the lower extremities.\n* Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBC's \u002FHPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)\n* In the opinion of the investigator, Individual is not a good candidate for participation in the study.",{"count":643,"type":21},200,[24],"A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).",[27,386,363,647],"Urinary Urge Incontinence",{"date":570,"type":37},{"date":650,"type":37},"2023-01-26",{"date":652,"type":21},"2031-12",{"name":654,"class":44},"Valencia Technologies Corporation",22]